FoundationOne Companion Diagnostic (F1CDx)
Four (4) total reports were sent to customers with clinically relevant variants requiring amendment, one (1) of which with an incorrect negative CDx claim. The remaining three (3) with tumor profiling result changes did not impact CDx indications.
Worldwide - US Nationwide distribution in the states of GA, NY and the country of Russia.
https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=Z-1747-2025